We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

US stocks were largely lower on Wednesday as investors digested a hotter-than-expected January inflation reading and ...

As President Trump threatens a wider trade war on EU and other allies, an obscure global tax battle could be one retaliatory ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

The Biomarkers Market is expected to grow from USD 79.3 billion in 2023-e to USD 187.4 billion by 2030, at a CAGR of 14.7% ...

Exploring sustainable blister packaging from the lens of material selection, quality regulations, machinability, and ...